Prosight Management LP Buys Shares of 76,100 Boston Scientific Corporation $BSX

Key Points

• Prosight Management LP bought a new stake of 76,100 shares of Boston Scientific (NYSE:BSX) in Q3, valued at about $7.43 million and representing roughly 1.7% of Prosight’s portfolio (its 22nd largest holding).
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 at an average $93.49 (≈$15.04 million), trimming his ownership by 10.23% to 1,411,735 shares; insiders now own about 0.50% of the company.
• Boston Scientific faces a filed class action alleging misrepresentation of U.S. electrophysiology procedure volumes, with multiple plaintiff firms actively soliciting lead‑plaintiff motions (deadline May 4, 2026), increasing potential litigation risk.

Prosight Management LP bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 76,100 shares of the medical equipment provider's stock, valued at approximately $7,430,000. Boston Scientific accounts for about 1.7% of Prosight Management LP's portfolio, making the stock its 22nd largest holding.

A number of other hedge funds also recently modified their holdings of the stock. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at approximately $26,000. Steph & Co. purchased a new stake in Boston Scientific in the third quarter worth $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 170 shares during the period. Financial Consulate Inc. purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.50% of the company's stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BSX. Robert W. Baird decreased their price objective on Boston Scientific from $118.00 to $101.00 and set an "outperform" rating for the company in a report on Thursday, February 5th. Canaccord Genuity Group cut their target price on shares of Boston Scientific from $112.00 to $109.00 and set a "buy" rating for the company in a research report on Tuesday, February 17th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Barclays lowered their price target on shares of Boston Scientific from $136.00 to $124.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. dropped their price target on shares of Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $108.00.

Boston Scientific Price Performance

BSX stock opened at $69.15 on Friday. The firm has a 50 day moving average of $82.47 and a 200-day moving average of $93.39. The firm has a market capitalization of $102.61 billion, a P/E ratio of 35.64, a price-to-earnings-growth ratio of 0.96 and a beta of 0.69. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the firm posted $0.70 EPS. Boston Scientific's revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.